STOCK TITAN

Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Poseida Therapeutics, Inc. (PSTX) announced its CEO will participate in a virtual fireside chat at a conference, focusing on cell therapy treatments for cancer and rare diseases.
Positive
  • None.
Negative
  • None.

SAN DIEGO, March 19, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company's President and Chief Executive Officer, Kristin Yarema, Ph.D., will participate in a virtual fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26, 2024 at 1:00pm PT | 4:00pm ET.

A live webcast of the fireside chat will be available on the Investors & Media Section of Poseida's website, www.poseida.com. A replay of the webcast will be available for approximately 90 days following the presentation.

About Poseida Therapeutics, Inc.
Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. The Company's approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System, Booster Molecule, and nanoparticle and hybrid gene delivery technologies as well as in-house GMP cell therapy manufacturing. The Company has formed a global strategic collaboration with Roche to unlock the promise of cell therapies for patients with hematological malignancies. Learn more at www.poseida.com and connect with Poseida on X and LinkedIn.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/poseida-therapeutics-to-present-at-hc-wainwright-2nd-annual-cell-therapy-virtual-conference-302092083.html

SOURCE Poseida Therapeutics, Inc.

Poseida Therapeutics CEO will participate on Tuesday, March 26, 2024, at 1:00pm PT | 4:00pm ET.

Investors can watch the live webcast on the Investors & Media Section of Poseida's website, www.poseida.com.

A replay of the webcast will be available for approximately 90 days following the presentation.
Poseida Therapeutics, Inc.

NASDAQ:PSTX

PSTX Rankings

PSTX Latest News

PSTX Stock Data

223.85M
54.57M
34.52%
47.58%
4.27%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO

About PSTX

poseida therapeutics, inc. is currently developing car-t and gene therapy products for cancer and orphan diseases. spinout of transposagen biopharmaceuticals early this year, poseida is also collaborating with j&j’s janssen to develop allogeneic car-t therapies against cancer. poseida boasts best-in-class genome engineering capabilities for effectively silencing target genes or inserting therapeutic genes and/or technologies. proprietary tools include piggybac™ dna modification system, nextgen™ crispr, xtn™ talen and footprint-free™ gene editing system, which are clean (synthetic and virus-free) and can be surgically precise. poseida aims to shuttle the first car-t and gene therapy product candidates into phase i clinical trials in early 2016. poseida is now hiring and searching for ambitious and motivated scientists desiring a fast-paced work environment with diverse research opportunities in the field of cellular and gene therapy.